MedTrace Logo

Effects of Different Fluid Transfusion Regimens On Glycocalyx In Patients Undergoing Thoracic Surgery.

NCT07192523 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-01-05

No results posted yet for this study

Summary

Introduction: Endothelial Glycocalyx (EG) composing of proteoglycans heparan sulfate (HS), syndecan, and plasma proteins forms a physiologically active surface layer on the vascular endothelium, regulates oncotic pressure. We aimed to compare the effects of two different fluid transfusion regimens on EG.

Materials and Methods: 41 patients with ASA I-III physical status were included in this prospective, randomized controlled study. We collected blood samples before anesthesia induction and after surgery to measure hemoglobin-hematocrit levels and biochemical parameters. Hemodynamic parameters were recorded every 15 minutes perioperatively. We divided the patients into two groups: Group R received 3 ml/kg/h, and Group L received 8 ml/kg/h of Ringer's lactate infusion. To assess endothelial damage, HS and syndecan levels, blood samples were taken after anesthesia induction(T1), after pneumonectomy or lobectomy(T2), and at the end of surgery(T3).

Conditions

  • Hypervolemia
  • Hypovolemia

Interventions

OTHER

Restrictive fluid therapy

Group Restrictive (Group R) received 3ml/kg/hr, crystalloid (Ringer Lactate).

OTHER

Liberal fluid therapy

Group Restrictive liberal received 8ml/kg/hr, crystalloid (Ringer Lactate).

Sponsors & Collaborators

  • Kocaeli Derince Education and Research Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-15
Primary Completion
2021-12-15
Completion
2025-08-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07192523 on ClinicalTrials.gov